Aims
-
Identify cellular and molecular mechanisms that promote effective anti‑tumor immunity or enable immune evasion within the tumor microenvironment.
-
Develop strategies that modulate immune pathways to enhance anti‑tumor responses while limiting immune‑related toxicity.
-
Evaluate novel cell‑based and non‑cell‑based immunotherapies through clinical trials.
The Immuno‑Oncology Program investigates how the immune system recognizes and responds to cancer, with the goal of developing immunotherapies that are both more effective and better tolerated. Researchers study the cellular and molecular pathways that shape immune activity within tumors, identifying factors that drive productive immune responses as well as those that enable immune evasion. These insights inform strategies to strengthen anti‑tumor immunity while reducing treatment‑related toxicity.
A major focus of the program is advancing new immunotherapeutic approaches, including engineered cell therapies, vaccines, viral‑based strategies, and other agents that modulate immune pathways. The program also leads investigator‑initiated clinical trials that evaluate these emerging treatments, supported by specialized cell‑manufacturing and immune‑monitoring resources. Through this integrated research and clinical effort, the Immuno‑Oncology Program accelerates the development of innovative immunotherapies designed to improve outcomes across a broad range of cancers.
